Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1478108

USP

Ofloxacin

United States Pharmacopeia (USP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H20FN3O4
Numéro CAS:
82419-36-1
Poids moléculaire :
361.37
Numéro MDL:
MFCD00226105
Code UNSPSC :
41116107
ID de substance PubChem :
329750600
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

ofloxacin, ofloxacin

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CC1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)

Clé InChI

GSDSWSVVBLHKDQ-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ofloxacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Ofloxacin Tablets
  • Ofloxacin Ophthalmic Solution
  • Levofloxacin

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Mahesh D Chavanpatil et al.
International journal of pharmaceutics, 316(1-2), 86-92 (2006-03-29)
Oral sustained release gastroretentive dosage forms offer many advantages for drugs having absorption from upper gastrointestinal tract and improve the bioavailability of medications that are characterized by a narrow absorption window. A new gastroretentive sustained release delivery system was developed
J P Monk et al.
Drugs, 33(4), 346-391 (1987-04-01)
Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Ciprofloxacin is the only other
S M Traeger et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 21(6), 1504-1506 (1995-12-01)
We describe four patients who had seizures while receiving ofloxacin; no other causes were evident. Common factors among all patients included advanced age and use of a high-dose regimen. The renal insufficiency of three patients and the timing of the
G A Gates
The Pediatric infectious disease journal, 20(1), 104-107 (2001-02-15)
To assess the safety of topical agents in the middle ear, animal studies were reviewed. Compared with aminoglycoside-containing preparations, which caused significant loss of hair cells in the basal turn of the cochlea, ofloxacin caused no loss of hair cells
C D Bluestone
The Pediatric infectious disease journal, 20(1), 111-115 (2001-02-15)
The safety and efficacy of ototopical preparations, such as ofloxacin, in the treatment of CSOM in infants and children do not currently have approval by the FDA even though ofloxacin is FDA-approved for treatment of CSOM that occurs in adults.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique